IL32 and metabolic dysfunction-associated steatotic liver disease: Further, IL-32 has an established role in the development of non-alcoholic fatty liver disease (35) and in attenuating experimental induced liver injury (36, 37), providing additional evidence for the pro-inflammatory role of IL-32 in targeted tissue (liver), possibly initiating tumorigenesis in this context, among genetically susceptible individuals.